Re: Accuracy of Glomerular Filtration Rate Estimation Based on Creatinine and Cystatin C for Monitoring Moderate Chronic Kidney Disease in Adults: Prospective, Longitudinal Cohort Study

Why It Matters

The low sensitivity limits eGFR’s utility for early detection of CKD progression, risking unnecessary referrals and patient anxiety while missing true declines, which could undermine quality‑based payment models in primary care.

Key Takeaways

• Combined creatinine‑cystatin C eGFR modestly improves GFR tracking
• Sensitivity for true CKD progression stays below 54% across equations
• High specificity leads to false‑positive alerts from minor eGFR fluctuations
• Recommend integrating albuminuria, slope, and clinical context into quality metrics

Pulse Analysis

Estimated glomerular filtration rate (eGFR) remains a cornerstone of chronic kidney disease (CKD) management, offering a non‑invasive proxy for kidney function. Clinicians traditionally rely on serum creatinine, and more recently cystatin C, to calculate eGFR, hoping that the combination improves accuracy. While the dual‑marker approach does tighten the correlation with measured GFR, the incremental benefit is modest, and the underlying equations were calibrated on heterogeneous populations, limiting their precision for individual monitoring.

The new longitudinal cohort analysis highlights a critical shortfall: even the best‑performing eGFR equations detect less than 54% of true CKD progression events, though they correctly rule out non‑progressors with high specificity. In primary‑care settings where eGFR thresholds drive quality metrics and referral pathways, this asymmetry fuels false‑positive alerts from normal biological variability. Physicians may order repeat labs, trigger specialist referrals, and cause patient anxiety without substantive evidence of disease worsening. The findings therefore challenge the current reliance on static eGFR cut‑offs for performance reporting.

A more nuanced strategy is emerging. Incorporating albuminuria trends, longitudinal eGFR slope, and broader clinical context can better differentiate true progression from noise. Health systems should recalibrate quality‑measure algorithms to weight these parameters, reducing unnecessary downstream costs while preserving early‑intervention opportunities. As pay‑for‑performance models evolve, aligning measurement tools with clinically meaningful outcomes will be essential for sustainable CKD care.